Register
Login:
Share:
Email Facebook Twitter




Vernalis Share Price (VER)



Share Price Information for Vernalis (VER)


Share Price: 56.00Bid: 56.00Ask: 58.00Change: 0.00 (0.00%)No Movement on Vernalis
Spread: 2.00Spread as %: 3.57%Open: 58.50High: 58.50Low: 56.00Yesterday’s Close: 56.00

Vernalis Plc Ord 1P

Vernalis is listed in the FTSE AIM 100, FTSE AIM All-Share
Vernalis is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
56.00

Share Price SpacerBid
56.00

Share Price SpacerAsk
58.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
38,062

Share Price SpacerOpen
58.50

Share Price SpacerHigh
58.50

Share Price SpacerLow
56.00

Share Price SpacerClose
56.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 445.12m £249.27m 10,000

52 Week High 87.25 52 Week High Date 10-SEP-2015
52 Week Low 44.50 52 Week Low Date 17-APR-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
16 27,273 10,789 -40.000 -1.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

05-Feb-16
17:04:02
58.00
67
Buy* 
56.00
58.00
38.86
Trade Type:
Ordinary
Bargain conditions apply

05-Feb-16
16:35:29
56.00
996
Sell* 
56.00
58.00
557.76
UT 
Trade Type:
Uncrossing Trade

05-Feb-16
16:16:17
57.86
10
Sell* 
57.50
58.50
5.79
Trade Type:
Ordinary




View more Vernalis trades >>

Directors Deals for Vernalis (VER)
Trade DateActionNotifierPriceCurrencyAmountHolding
15-Oct-15Exercise of option
Trade Notifier Information for Vernalis
David Mackney held the position of CFO at Vernalis at the time of this trade.
 David Mackney
19.6GBX45,918365203
08-Oct-15Exercise of option
Trade Notifier Information for Vernalis
Ian Garland held the position of CEO at Vernalis at the time of this trade.
 Ian Garland
19.6GBX45,918704857
05-May-15Buy
Trade Notifier Information for Vernalis
Nigel Sheail held the position of Non-Executive Director at Vernalis at the time of this trade.
 Nigel Sheail
59.9GBX84,000294000
View more Vernalis directors dealings >>


Date/TimeAuthorSubjectShare PriceOpinion
6 Jan '16PazuzuRNS out70.00No Opinion
6 January 2016
LSE: VER

Vernalis Announces Corvus Pharmaceuticals, Inc. as its Worldwide Licensee for their Adenosine Antagonist Program

Adenosine antagonists under development for use in immuno-oncology

Vernalis plc ("Vernalis" or the "Company") today announces Corvus Pharmaceuticals, Inc. ("Corvus") as its licensee for their adenosine antagonist program.

In February 2015, the Company licensed exclusive, worldwide rights in its adenosine receptor antagonist programme for use in all therapeutic applications to Corvus, a U.S.-based biotechnology company. At the time the name of the company was not disclosed and nor was the initial therapeutic focus.

Corvus was launched through a $33.5 million Series A fundraising in 2014 by the founder and former senior management at Pharmacyclics Inc. and it raised a further $75m (Series B) in September 2015.

The lead molecule, CPI-444 is a patented small molecule that has been evaluated in Phase I and II clinical trials under an IND in the U.S. Corvus brings a wealth of clinical and commercial expertise and experience and is looking to develop CPI-444 for immuno-oncology, with clinical studies expected in 2016.

Ian Garland, CEO of Vernalis commented "We are pleased to make public that Corvus is our licensee and we are excited about the development of CPI-444 in an immuno-oncology setting."

-- ends --
26 Nov '15EdenfundHoldings66.25No Opinion
Woodford Fund 23%

Invesco 35.97%

Neil Woodford seems to be building up his stake slowly.
16 Oct '15EdenfundWooodford fund72.00No Opinion
Woodford fund has increased its holding to 22.2%
2 Oct '15EdenfundBroker report on Moxatag.79.00No Opinion
Vernalis antibiotic buy 'sensible' says broker
Share
09:50 02 Oct 2015
“It enables Vernalis to make more efficient use of its sales team"
Vernalis antibiotic buy 'sensible' says broker
Canaccord expects Moxatag to be launched early in 2016.
Vernalis’ (LON:VER) acquisition of Moxatag, the only approved once-daily formulation of the antibiotic amoxicillin, is a smart move, brokers said today.

In consideration Vernalis has paid owner Pragma an undisclosed up-front cash payment with a further payment with a finished dose product.

Vernalis will also take over its sale and pay Pragma royalties on net sales and further potential sales related milestones.

Approved in the US in 2008, Moxatag is used in the treatment of tonsillitis and other throat infections. It is protected by six Orange Book listed patents, the last of which expires in 2027.

Ian Garland, Vernalis’s chief executive, said Moxatag was another important step towards its transition to a commercial specialty pharmaceutical company.

The drug had not been actively marketed since 2010 and its acquisition enables Vernalis to make better use of the infrastructure put in place with the US launch of cough and cold treatment Tuzistra XR.

Canaccord added it expects Moxatag to be launched in early 2016.

“As antibiotics can be prescribed in combination with cough-cold products during flu season it is a sensible companion product for Tuzistra XR.

“It enables Vernalis to make more efficient use of its sales team, and having two products in the portfolio should make getting sales time to with a doctor simpler.

Buy with a 98p target price said the broker.

Shares rose 2% to 78.5p.

Share
2 Oct '15EdenfundBroker ups price target.79.00No Opinion
Vernalis plc (LON:VER) had its target price upped by equities researchers at Canaccord Genuity from GBX 92 ($1.40) to GBX 98 ($1.49) in a report issued on Tuesday, Market Beat reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 25.04% from the stock’s previous close.
Shares of Vernalis plc (LON:VER) opened at 72.920 on Tuesday. Vernalis plc has a 1-year low of GBX 44.45 and a 1-year high of GBX 88.29. The stock’s market capitalization is GBX 322.54 million. The firm’s 50-day moving average is GBX 80.79 and its 200 day moving average is GBX 66.39.

Other research analysts also recently issued research reports about the company. N+1 Singer restated a “buy” rating on shares of Vernalis plc in a research note on Tuesday. Stifel Nicolaus reiterated a “buy” rating and set a GBX 103 ($1.57) target price on shares of Vernalis plc in a research note on Thursday, June 11th.
Vernalis plc is a United Kingdom-based research and development- stage pharmaceutical company. Vernalis has one marketed product along with a portfolio of development and drug discovery programmes. Vernalis has nine active cooperation, four covering programmes in preclinical through to Phase II development and four active drug discovery cooperation. Its commercial pipeline contains CCP-01, CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the UK, Rest of Europe, North America and Rest of the
2 Oct '15EdenfundMoxatag79.00No Opinion
02 October 2015

2 October 2015

LSE: VER

Vernalis plc acquires US rights to MOXATAG(R)

First and only approved once-a-day formulation of the antibiotic, amoxicillin

Exemplifies strategy for further expanding product portfolio

Vernalis plc today announces that it has acquired the US rights to MOXATAG(R) (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC ("Pragma"). MOXATAG(R) is the first and only approved once-daily formulation of the antibiotic, amoxicillin.

In consideration for the acquisition, Vernalis has paid to Pragma an undisclosed up-front cash payment and will make a further payment upon successful manufacture of re-launch finished dose product, expected to be by the end of 2015. The consideration payable does not materially impact the Group's cash resources. Under the terms of the transaction, Vernalis will take over supply chain responsibility and will pay Pragma royalties on net sales and further potential sales related milestones.

Approved by the FDA in 2008, MOXATAG(R) is a penicillin-class antibacterial indicated for the treatment of tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in adults and paediatric patients 12 years of age or older. It was approved based on a Phase III efficacy study and is protected by six Orange Book listed patents, the last of which expires in 2027. It has not been actively promoted since 2010.

Ian Garland, CEO of Vernalis commented, "The acquisition of MOXATAG(R) is another important step in our transition to a commercial specialty pharmaceutical company. We are delighted that we have been able to quickly expand our primary care product portfolio and leverage our newly established US commercial infrastructure following the recent US launch of TUZISTRA(TM) XR, our extended-release cough cold oral suspension. MOXATAG(R) has a strong fit with our target physician audience for TUZISTRA(TM) XR and we look forward to re-launching the product in early 2016 and to its contribution to our commercial business".

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Vernalis (VER) >>

Please login or register to post a message on Share Chat.



Vernalis Plc Ord 1P home pageWebsite: Vernalis Plc Ord 1P
Website Description: Vernalis corporate website



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.